A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. Prat, A., Lluch, A., Turnbull, A. K., Dunbier, A. K., Calvo, L., Albanell, J., de la Haba-Rodríguez, J., Arcusa, A., Chacón, J. I., Sánchez-Rovira, P., Plazaola, A., Muñoz, M., Paré, L., Parker, J. S., Ribelles, N., Jimenez, B., Bin Aiderus, A. A., Caballero, R., Adamo, B., Dowsett, M., Carrasco, E., Martín, M., Dixon, J. M., Perou, C. M., & Alba, E. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23(12):3035–3044, 2017.
doi  abstract   bibtex   
Purpose: Hormone receptor-positive (HR(+)) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified.Experimental Design: Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR(+)/HER2(-) disease randomly assigned to neoadjuvant multiagent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based chemoendocrine score (CES). CES's predictive ability was evaluated in 4 independent neoadjuvant data sets (n = 675) and 4 adjuvant data sets (n = 1,505). The association of CES, intrinsic biology, and PAM50 risk of relapse (ROR) was explored across 6,007 tumors.Results: Most genes associated with endocrine sensitivity were also found associated with chemotherapy resistance. In the chemotherapy test/validation data sets, CES was independently associated with pathologic complete response (pCR), even after adjusting for intrinsic subtype. pCR rates of the CES endocrine-sensitive (CES-E), uncertain (CES-U), and chemotherapy-sensitive (CES-C) groups in both data sets combined were 25%, 11%, and 2%, respectively. In the endocrine test/validation data sets, CES was independently associated with response. Compared with ROR, \textgreater90% of ROR-low and ROR-high tumors were identified as CES-E and CES-C, respectively; however, each CES group represented \textgreater25% of ROR-intermediate disease. In terms of survival outcome, CES-C was associated with poor relapse-free survival in patients with ROR-intermediate disease treated with either adjuvant endocrine therapy only or no adjuvant systemic therapy, but not in patients treated with (neo)adjuvant chemotherapy.Conclusions: CES is a genomic signature capable of estimating chemoendocrine sensitivity in HR(+) breast cancer beyond intrinsic subtype and risk of relapse. Clin Cancer Res; 23(12); 3035-44. ©2016 AACR.
@article{prat_pam50-based_2017,
	title = {A {PAM50}-{Based} {Chemoendocrine} {Score} for {Hormone} {Receptor}-{Positive} {Breast} {Cancer} with an {Intermediate} {Risk} of {Relapse}},
	volume = {23},
	issn = {1078-0432},
	doi = {10.1158/1078-0432.CCR-16-2092},
	abstract = {Purpose: Hormone receptor-positive (HR(+)) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified.Experimental Design: Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR(+)/HER2(-) disease randomly assigned to neoadjuvant multiagent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based chemoendocrine score (CES). CES's predictive ability was evaluated in 4 independent neoadjuvant data sets (n = 675) and 4 adjuvant data sets (n = 1,505). The association of CES, intrinsic biology, and PAM50 risk of relapse (ROR) was explored across 6,007 tumors.Results: Most genes associated with endocrine sensitivity were also found associated with chemotherapy resistance. In the chemotherapy test/validation data sets, CES was independently associated with pathologic complete response (pCR), even after adjusting for intrinsic subtype. pCR rates of the CES endocrine-sensitive (CES-E), uncertain (CES-U), and chemotherapy-sensitive (CES-C) groups in both data sets combined were 25\%, 11\%, and 2\%, respectively. In the endocrine test/validation data sets, CES was independently associated with response. Compared with ROR, {\textgreater}90\% of ROR-low and ROR-high tumors were identified as CES-E and CES-C, respectively; however, each CES group represented {\textgreater}25\% of ROR-intermediate disease. In terms of survival outcome, CES-C was associated with poor relapse-free survival in patients with ROR-intermediate disease treated with either adjuvant endocrine therapy only or no adjuvant systemic therapy, but not in patients treated with (neo)adjuvant chemotherapy.Conclusions: CES is a genomic signature capable of estimating chemoendocrine sensitivity in HR(+) breast cancer beyond intrinsic subtype and risk of relapse. Clin Cancer Res; 23(12); 3035-44. ©2016 AACR.},
	language = {eng},
	number = {12},
	journal = {Clinical Cancer Research: An Official Journal of the American Association for Cancer Research},
	author = {Prat, Aleix and Lluch, Ana and Turnbull, Arran K. and Dunbier, Anita K. and Calvo, Lourdes and Albanell, Joan and de la Haba-Rodríguez, Juan and Arcusa, Angels and Chacón, José Ignacio and Sánchez-Rovira, Pedro and Plazaola, Arrate and Muñoz, Montserrat and Paré, Laia and Parker, Joel S. and Ribelles, Nuria and Jimenez, Begoña and Bin Aiderus, Abdul Aziz and Caballero, Rosalía and Adamo, Barbara and Dowsett, Mitch and Carrasco, Eva and Martín, Miguel and Dixon, J. Michael and Perou, Charles M. and Alba, Emilio},
	year = {2017},
	pmid = {27903675},
	pmcid = {PMC5449267},
	keywords = {Article, Oncologia},
	pages = {3035--3044},
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021